Early clinical experience with subcutaneous GR43175 in acute migraine: An overview-Reference-Cited by-同舟云学术

Early clinical experience with subcutaneous GR43175 in acute migraine: An overview

Published:1989-09 Issue:9_suppl Volume:9 Page:73-77
ISSN:0333-1024
Container-title:Cephalalgia
language:en
Short-container-title:Cephalalgia

Author:

Tfelt-Hansen P¹,Brand J²,Dano P³,Doenicke A⁴,Findley LJ⁵,Iversen HK⁶,Melchart D⁴,Sahlender HM⁶

Affiliation:

1. Department of Neurology, University Hospital, Gentofte, Denmark

2. Migraine Clinic, Koenigstein, West Germany

3. Hôpital d'Instruction des Armées Laveran, Marseille, France

4. Institut für Anaesthesiologie, Ludwig-Maximilians-Universität-München, Munich, West Germany

5. Department of Neurology, Oldchurch Hospital, Romford, Essex UK

6. Artzin für Anaesthesiologie, Heidelberg, West Germany

Abstract

In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT1-like receptor agonist. Response rates after 20–30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials.

Publisher

SAGE Publications

Subject

Clinical Neurology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1111/J.1468-2982.1989.TB00076.X

Reference4 articles.

1. POSSIBLE BENEFIT OF GR43175, A NOVEL 5-HT1-LIKE RECEPTOR AGONIST, FOR THE ACUTE TREATMENT OF SEVERE MIGRAINE

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Migraine;Reference Module in Biomedical Sciences;2021

2. Migraine recurrence is not associated with depressive or anxiety symptoms. Results of a randomized controlled trial;Cephalalgia;2010-05-06

3. What can be learned from the history of recurrence in migraine? A comment;The Journal of Headache and Pain;2009-08-25

4. History of the Use of Ergotamine and Dihydroergotamine in Migraine From 1906 and Onward;Cephalalgia;2008-08

5. Role of KATPChannels in the Regulation of Rat Dura and Pia Artery Diameter;Cephalalgia;2005-04